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Available online 31 May 2016Conformational changes involving the amino terminus of the tau protein are among the earliest alterations asso-
ciated with tau pathology in Alzheimer's disease and other tauopathies. This region of tau contains a phospha-
tase-activating domain (PAD) that is aberrantly exposed in pathological forms of the protein, an event that is
associated with disruptions in anterograde fast axonal transport. We utilized four antibodies that recognize the
amino terminus of tau, TNT1, TNT2 (a novel antibody), Tau12, and Tau13, to further study this important region.
Using scanning alaninemutations in recombinant tau proteins, we reﬁned the epitopes of each antibody.We ex-
amined the antibodies' relative abilities to speciﬁcally label pathological tau in non-denaturing and denaturing
assays to gain insight into some of the mechanistic details of PAD exposure. We then determined the pattern
of tau pathology labeled by each antibody in human hippocampal sections at various disease stages in order to
characterize PAD exposure in the context of disease progression. The characteristics of reactivity for the antibod-
ies fell into two groups. TNT1 and TNT2 recognized epitopes within amino acids 7–12 and speciﬁcally identiﬁed
recombinant tau aggregates and pathological tau from Alzheimer's disease brains in a conformation-dependent
manner. These antibodies labeled early pre-tangle pathology from neurons in early Braak stages and colocalized
with thiazine red, a marker of ﬁbrillar pathology, in classic neuroﬁbrillary tangles. However, late tangles were
negative for TNT1 and TNT2 indicating a loss of the epitope in later stages of tangle evolution. In contrast,
Tau12 and Tau13 both identiﬁed discontinuous epitopes in the amino terminus and were unable to differentiate
between normal and pathological tau in biochemical and tissue immunohistological assays. Despite the close
proximity of these epitopes, the antibodies demonstrated remarkably different abilities to identify pathological
changes in tau indicating that detection of conformational alterations involving PAD exposure is not achieved
by all N-terminal tau antibodies and that a relatively discrete region of the N-terminus (i.e., amino acids 7–12,
the TNT1 and TNT2 epitope) is central to the differences between normal and pathological tau. The appearance
of PAD in early tau pathology and its disappearance in late-stage tangles suggest that toxic forms of tau are asso-
ciatedwith the earliest forms of tau deposits. Collectively, these ﬁndings demonstrate that the TNT antibodies are
usefulmarkers for early conformational display of PAD and provide information regarding conformational chang-
es that have potential implications in the toxic mechanisms of tau pathology.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Tau
Alzheimer's disease
Tauopathies
Neurodegeneration
Protein misfolding
Protein aggregation
Conformation
Antibodieshatase-activating domain; ThR,
; TNT, TauN-terminal antibody;
5,5'-tetramethylbenzidine; TBS,
3,3'-diaminobenzidine; IHC,
, glycogen synthase kinase.
tional Science and Molecular
iversity, 333 Bostwick Ave NE,
mbs),
hc.msu.edu (N.M. Kanaan).
ect.com).
. This is an open access article under1. Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder character-
ized by pathological aggregation of tau protein and the amyloid-β pep-
tide leading to the formation of intracellular neuroﬁbrillary tangles
(NFTs) and extracellular senile plaques, respectively (Braak and Braak,
1991). There is an association between tau pathology deposition and
loss of cells and synapses, but a growing body of evidence suggests
that NFTs may not be the cause of neurotoxicity (Bobinski et al., 1997;
Bussiere et al., 2003; Gomez-Isla et al., 1997; Morsch et al., 1999;
Santacruz et al., 2005; Spires-Jones et al., 2008; Wittmann et al., 2001;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the early pre-tangle alterations in tau may lead to toxicity and why
this toxicity is apparently lost or reduced in mature ﬁbrillar pathology.
Changes in tau conformation may play an important role in the de-
velopment of early tau pathology and tau-mediated toxicity. Tau is tra-
ditionally described as a disordered protein; however, evidence
suggests that tau proteins fold into multiple conformations. Initial evi-
dence of tau folding was derived from the description of the discontin-
uous Alz50 andMC1 epitopes, which label otherwise normal-appearing
neurons early in disease progression and prior to NFT formation
(Carmel et al., 1996; Hyman et al., 1988; Jicha et al., 1999, 1997). The
disease speciﬁcity of these two antibodies indicated that tau undergoes
a conformational change involving a close association of theN-terminus
and microtubule-binding domains in Alzheimer's disease. More recent-
ly, a global conformation known as the global hairpin or “paperclip”
conformation, where the N- and C-termini are in close proximity and
the C-terminus and microtubule-binding domains are interacting, was
described (Jeganathan et al., 2006). Folding of the N-terminus into this
conformation is impaired by mimicking phosphorylation epitopes (e.g.
the AT8 site) associated with Alzheimer's disease (Goedert et al.,
1995; Greenberg et al., 1992; Jeganathan et al., 2008; Mercken et al.,
1992).
Changes in the conformations of tau are particularly important be-
cause they can directly affect the function of the protein and its toxic
role in disease. One key example involves the recently identiﬁed phos-
phatase-activating domain (PAD)motif, seated in the extremeN-termi-
nus of tau, whose exposure depends upon changes in tau folding
(Kanaan et al., 2011). Recently, we developed a monoclonal antibody,
Tau N-terminal 1 (TNT1), which identiﬁes PAD exposure in non-dena-
turing assays (Kanaan et al., 2011). Evidence from the TNT1 antibody
suggests that PAD is exposed in pathological forms of tau, including ag-
gregated recombinant tau and tau from AD brains, but not monomeric
recombinant tau and tau isolated from non-demented human brains
(Kanaan et al., 2015, 2012, 2011). Aberrant exposure of this motif in
disease-related forms of tau disrupts fast axonal transport, a process
critical to neuron function and viability, through a signaling cascade
involving PP1 and GSK3 (Kanaan et al., 2011; LaPointe et al., 2009).
This links a direct toxic mechanism with conformational changes ex-
posing the N-terminus of the protein and induced by pathological
alterations in tau (e.g. aggregation or phosphorylation). This has
shifted our focus to establishing how presentation of PAD is affected
in Alzheimer's disease and its implications for progression of the
disease.
In order to identify some mechanistic details of PAD exposure, we
performed a detailed characterization of several N-terminal tau anti-
bodies (TNT1, TNT2, Tau12, and Tau13) for their abilities to differential-
ly recognize pathological, PAD-exposed tau or normal forms of the tau
protein. The epitopes of these antibodies displayed distinct patterns of
reactivity despite only small differences in their epitopes. The TNT1
(Kanaan et al., 2011) and TNT2 (a newly described reagent) antibodies
displayed strong, conformation-dependent reactivity with pathological
forms of tau, but not normal tau in non-denaturing assays. In contrast,
Tau12 (Horowitz et al., 2004) and Tau13 (Ghoshal et al., 2002) did not
detect differences between pathological and normal tau, demonstrating
that not all N-terminal antibodies are useful for this purpose and the rel-
evant conformational changes involve, and may be limited to, amino
acids 7–12. The TNT antibodies labeled diffuse, pre-tangle pathology
in hippocampal tissue sections from Braak stages I–VI cases. The TNT1
and TNT2 antibodies colocalized with pathology identiﬁed by the
early, conformation-speciﬁc Alz50 antibody, and remained in classical
NFTs but did not co-label in thiazine red (ThR)-positive late-stage
NFTs (e.g. ghost tangles). These ﬁndings demonstrate that TNT1 and
TNT2 are useful reagents to differentiate normal from pathological,
PAD-exposed forms of the tau protein, and that PAD exposure is an
early conformational change in tau that occurs as pathology begins to
accumulate in neurons.2. Materials and methods
2.1. Recombinant tau proteins
The full-length human tau protein construct (2N4R/hT40) contain-
ing a C-terminal 6xHis tag in the pT7 plasmid was used to produce re-
combinant tau protein as described (Kanaan et al., 2011). Site-directed
mutagenesis (Agilent Quikchange Lightning, Santa Clara, CA, 210519-
5)was used to introduce the followingmutations in the hT40 construct:
E3A, P4A, R5A, Q6A, E7A, FE8-9AA, V10A, M11A, E12A, D13A/H14A/
A15A/G16A/T17A (X13-17A), Y18A/G19A/L20A/G21A (X18-21A), or
D22A/R23A/K24A (X22-24A). In addition, wild-type versions of the
other ﬁve human tau isoform proteins (2N3R/hT39, 1N4R/hT34,
1N3R/hT37, 0N4R/hT24, and 0N3R/hT23) were produced. These con-
structs were transformed into T7 Express competent cells (New En-
gland Biosciences, Ipswich, MA, C2566I). 125 ml of Luria Broth was
inoculated with the bacteria and grown overnight at 25 °C until it
reached an OD600 value of 0.8–1.0. IPTG was added to the ﬂask at a
ﬁnal concentration of 1 mM and incubated at 37 °C for 2 h. The cells
were centrifuged at 8000 × g for 10 min, washed with saline buffer
and centrifuged again at 8000 × g for 10 min. The pellet was frozen at
−80 °C. The cells were resuspended in buffer (50 mM NaCl, 1 mM
Tris, and 500 nM imidazole, with protease inhibitors at 10 μg/ml of
pepstatin, leupeptin, bestatin, and aprotinin, and 1 mM PMSF, pH 8.0)
and lysed by sonication (20 pulses of 5 s each at power setting of 3,
Misonix XL-2000) on ice. Protease inhibitorswere again added to the ly-
sate at the same concentrations as above along with Brij 35 to 0.1%. The
sample was then centrifuged at 107,000 × g for 20 min at 4 °C. Protease
inhibitors and 10% glycerol were added to the supernatant before load-
ing it onto 1 ml of Talon metal afﬁnity resin (Clontech, Mountain View,
CA, #635502). After a 20 ml buffer wash, the protein was eluted into
1 ml fractions by adding 10 ml of elution buffer (50 mM NaCl, 1 mM
Tris, and 100 mM imidazole with 2 mM PMSF). The samples were ana-
lyzed by SDS-PAGE and Coomassie staining and fractions with protein
were combined and dithiothreitol (DTT) was added to 1 mM ﬁnal
concentration.
Protein concentrations were determined by SDS Lowrywhere 200 μl
of the proteins were added to 200 μl of SDS solution (2% SDS, 5% β-
mercaptoethanol, 10% glycerol, 62.5 mM Tris, pH 6.8), respectively,
along with buffer-only blank samples. Protein standards of 0, 2, 4, 8,
16, and 32 μg were generated using a 2 mg/ml bovine serum albumin
(BSA) stock (Thermo Fisher Scientiﬁc, Waltham, MA, #23209) and
adding SDS solution to a total volume of 100 μl. 1 ml of 10% perchloric
acid/1% phosphotungstic acid was added to each sample, vortexed,
and brieﬂy spun in microcentrifuge before a 1 h incubation on ice. The
samples were then centrifuged at 18,000 × g for 15 min at 4 °C and
the supernatant was removed. After the protein pellet had completely
dried, it was dissolved in 1ml of Lowry solution (0.01% CuSO4, 0.02% so-
dium potassium tartate, and 2% sodium carbonate in 0.1 N sodium hy-
droxide) and incubated at RT for 10 min. 100 μl of Folin–Ciocalteu's
phenol reagent (diluted 1:1 in water, Sigma–Aldrich, St. Louis, MO,
F9252) was added and incubated for 30–45 min at RT. 100 μl of each
sample was added, in duplicate, to a clear 96-well plate and the absor-
bances were read at 750 nm. The total protein concentrations were in-
terpolated from the BSA standard curve (r2 = 0.98). The protein was
aliquoted into 10–50 μl and frozen at−80 °C.
2.2. Animals
An adult male Sprague–Dawley rat (Harlan, Indianapolis, IN, 002),
an adult male C57BL/6J mouse (The Jackson Laboratory, Bar Harbor,
ME, 000664), and an adult male tau knockout mouse (The Jackson Lab-
oratory, 007251) were used to obtain brain lysate samples. The animals
were sacriﬁced approximately 7 days after delivery and were
transcardially perfused with 0.9% saline with heparin (10,000 U/L) to
clear the blood. The frontal cortex was microdissected and stored at
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terizingN-terminal antibodies (see below). All animal studieswere per-
formed in accordance with standard regulations and were approved by
the Michigan State University Institutional Animal Care and Use
Committee.2.3. Generation of the tau N-terminal 2 (TNT2) antibody
This is the ﬁrst description of the novel mousemonoclonal TNT2 an-
tibody. TNT2 was generated by immunizing mice with a peptide of
amino acids 2–18 of hT40 (2AEPRQEFEVMEDHAGTY 18) conjugated to
KLH as described (Kanaan et al., 2011). Brieﬂy, BALB/c female mice
(Jackson Laboratories, #001026) were immunized subcutaneously
every 3 weeks for 5 months. After immunization, the splenocytes
were fused to SP2/o myeloma cells and positive clones that reacted
with PAD in indirect ELISAs (as described below) were subcloned four
times. Isotype strips were used to determine that TNT2 is an IgG1. A
CELLine Classic 1000 bioreactor (Sartorius AG, DC-90005) was used to
produce TNT2 before puriﬁcation with protein A sepharose (GE
Healthcare, Little Chalfront, UK, #17-1279-02) using methods similar
to those previously described (Kanaan et al., 2011). Puriﬁed TNT2 was
dialyzed into antibody storage buffer (10 mM HEPES, 500 mM NaCl,
50% glycerol, pH 7.4), adjusted to 1 mg/ml, aliquoted and stored at
−80 °C.2.4. Rodent brain lysates for antibody characterization
Tissue samples from the frontal cortex of a rat, mouse, and tau
knockout mouse (from above) were processed to assess the species
cross-reactivity and speciﬁcity of TNT1, TNT2, Tau12, and Tau13. Tissue
pieceswere homogenized in 375 μl lysis buffer (0.8MNaCl, 10% sucrose,
1 mM EDTA, 10 mM Tris, pH 7.4) containing protease inhibitors (as
above) and phosphatase inhibitors (β-glycerophosphate and sodium
orthovanadate at 1 mM) by sonication (power setting = 3, 20 × 5 s
pulses on ice). Debris was removed by spinning samples at 12,000 × g
for 10min. The resulting supernatantwas assessed for total protein con-
centration using the Bradford assay where 1, 2, 4, and 8 μl of sample
were diluted to 160 μl of water. Triplicate BSA standards of 5, 10, 20,
40, and 80 μg were generated through serial dilutions from a 2 mg/ml
stock. Corresponding control samples were made with lysis buffer at
the same volumes as the BSA standards. 160 μl of all samples were incu-
bated with 40 μl of dye solution for 5 min. The absorbances of 160 μl of
the sample–reagent mixes were measured at 595 nm in a clear micro-
plate. The absorbances from the buffer-only control samples were
subtracted from the BSA standards and samples. Then a linear standard
curve was generated from the BSA standard absorbance values (r2 =
0.997). The protein concentrations of the samples were interpolated
using the standard curve. Samples were stored at−80 °C until use in
western blotting as described below.2.5. Arachidonic acid-induced tau aggregation in vitro
Recombinant tau monomer and aggregate samples were generated
bymaking a 400 μl reactionwith 2 μMhT40 tau containing a C-terminal
6xHis tag in polymerization buffer (5 mM DTT, 100 mM NaCl, 100 μM
EDTA, and 10 mM HEPES at pH 7.64). The reaction was split in half
and 7.5 μl of 2 mM arachidonic acid in ethanol was added to a ﬁnal con-
centration of 75 μM in order to induce tau polymerization in the aggre-
gate sample. The monomer sample received 7.5 μl of ethanol as a
control. The reactionswere allowed to proceed overnight and the extent
of aggregation was conﬁrmed using right-angle laser light scattering
(Gamblin et al., 2000). The aggregated tau sample produced the expect-
ed level of light scattering (~150 a.u.). Aliquots of the samples were
stored at−80 °C until used in assays outlined below.2.6. Tau extraction from human frontal cortex tissue
Fresh frozen tissue samples from the frontal cortex of age-matched
non-demented (control, n= 6) and severe AD cases (n= 6) were ob-
tained from the Brain Bank of the Cognitive Neurology and Alzheimer's
Disease Center at Northwestern University (see Supplemental Table 1
for details on human subjects). Soluble tau and sarkosyl-insoluble tau
fractions were obtained as described previously (Kanaan et al., 2015).
The tissue was suspended in 10 volumes of Brain Homgenization Buffer
(50mMTris, pH 7.4, 274mMNaCl, 5 mMKCl with pepstatin, leupeptin,
bestatin, and aprotinin protease inhibitors at 10 μg/ml and PMSF at
1 mM). The tissue was homogenized with a Tissue Tearor Model 985-
370 on setting #4 for 3 × 10 s then centrifuged at 27,000 × g for
20 min at 4 °C. The supernatant fraction was collected (soluble tau)
and the pellet was resuspended in 5 volumes of 1X Brain Pellet Homog-
enization Buffer (800 mMNaCl, 10% sucrose, 10 mM Tris, pH 7.4, 1 mM
EGTA, and 1 mM PMSF). The pellet was again homogenized at #4 for
3 × 10 s and spun at 27,000 × g for 20 min at 4 °C. Sarkosyl powder
(to 1% ﬁnal amount) was added to the supernatant and incubated for
1 h at 37 ° C. After the sarkosyl incubation, sample was spun at
200,000 × g for 1 h at 4 °C. The pellet was resuspended in 1 ml of
Brain Pellet Homogenization buffer as the sarkosyl-insoluble tau frac-
tion. An SDS Lowry protein assay was performed on the soluble tau
(4 μl + 96 μl SDS solution) and insoluble tau (using 16 μl + 84 μl SDS
solution) fractions, as described above, to determine total protein con-
centrations. The fractions were aliquoted and stored at −80 °C until
used in assays outlined below.
2.7. Indirect enzyme-linked immunosorbent assays (ELISAs)
Indirect ELISAs were used to determine the relative afﬁnities of
TNT1, TNT2, Tau12, and Tau13 antibodies. Recombinant hT40 tau pro-
tein monomer was diluted to 2 ng/μl and 50 μl was added to the wells
of a 96-well high-binding plate (Corning, Corning, NY, #3590), then in-
cubated at room temperature for 1 h and washed 2× with ELISA wash
buffer (100 mM boric acid, 25 mM sodium tetraborate decahydrate,
75 mM sodium chloride, 250 μM thimerosal, 0.4% BSA (Thermo Fisher
Scientiﬁc, BP1600-100), and 0.1% Tween-20). The wells were blocked
with 200 μl of 5% non-fat dry milk in wash buffer for 1 h and washed
2×. The primary antibodies were serially diluted in 1:2 intervals from
100 ng/ml to 48.8 pg/ml and 50 μl was added to the wells for 2 h then
washed 4× with wash buffer. The wells were then incubated for 1 h
with 50 μl of horseradish peroxidase (HRP)-conjugated horse anti-
mouse secondary antibody (Vector Laboratories, Burlingame, CA, PI-
2000) at a dilution of 1:5000, washed 4×, then developed with 50 μl
of 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma, T0440). The develop-
ment was stopped after 5 min with 50 μl of 3.6% H2SO4 and absorbance
was read at 450 nm. Blankwellswithout tau proteinwere used to deter-
mine background absorbance. The absorbance valueswere converted to
percent of light absorbed (a linear scale) using the following equation,
%A = (1 − 10−x)*100, where x is the absorbance value. The data
were ﬁt to a sigmoidal dose-response curve (all r2 N 0.99).
2.8. Sandwich ELISAs
Recombinant tau sandwich ELISAs were used to measure the differ-
ential reactivity of TNT1, TNT2, Tau12, or Tau13 for monomeric and ag-
gregated tau samples in non-denaturing conditions. Capture antibodies
were diluted to 1 ng/μl and 50 μl was added per well in a 96-well plate
and allowed to incubate for 1 h. All incubationswere carried out at room
temperature and on a shaker. Thewells were washed 2× in ELISA wash
buffer. Thewells were blockedwith 200 μl of wash buffer containing 5%
non-fat dry milk for 1 h and then rinsed 2× with wash buffer. The
monomer and aggregated samples were serially diluted in tris buffered
saline (TBS, 150mMNaCl, 50mMTris, pH 7.4) from 200 nM to 12.2 pM
at 1:4 intervals and 50 μl was added to thewells for 90min thenwashed
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rabbit antibody (Berry et al., 2004)) was diluted at 1:10,000 in milk
and 50 μl was added to the plates for 90 min. The wells were washed
4 times and 50 μl of HRP-conjugated goat anti-rabbit (Vector Laborato-
ries, PI-2000) detection secondary antibodywas added at a 1:5000 dilu-
tion in milk for 1 h. Then the wells were washed 4× in wash buffer
followed by development with 50 μl of TMB for 5–20 min, stopped
with addition of 50 μl of 3.6% H2SO4, and absorbance was read at
450 nm and converted to %A as above. The data were ﬁt to a sigmoidal
dose–response curve.
Sandwich ELISAs were repeated as above, except where noted, with
soluble and sarkosyl-insoluble tau fractions from control and AD human
brain samples. All capture antibodies (TNT1, TNT2, Tau12, Tau13, and
PHF1) were diluted 1:1000 from 1 mg/ml stock solutions. For the solu-
ble tau samples, 50 μl containing 20 μg of total protein (0.4mg/ml; dilut-
ed in borate saline buffer) was added to each well, while 50 μl
containing 2.5 μg total protein was used for the sarkosyl-insoluble sam-
ples. For 1 control and 2 AD cases, the maximum sample available was
0.03 mg/ml in 50 μl of the control case and 0.016 mg/ml in 50 μl for
the AD cases. The R1 tau antibody and HRP-conjugated anti-rabbit anti-
bodies were used as above. The ELISAs were developed for 5–9 min.
Since brain lysates contained unknown amounts of tau, independent in-
direct ELISAs with the R1 detection antibody were performed simulta-
neously for each capture antibody following the above indirect ELISA
method. For these standard curve indirect ELISAs, recombinant hT40
tau monomer samples ranged from 0.98 to 250 ng/well and were de-
tectedwith the R1 antibody. This provided a standard curve for us to in-
terpolate the amount of tau bound by the capture antibodies in the
human sample sandwich ELISAs as described in detail previously
(Kanaan et al., 2015). The absorbance values from the R1 indirect
ELISA standard curve values were ﬁt to a nonlinear one-phase associa-
tion equation (all r2 N 0.98). The concentrations of tau detected in
each of the sandwich ELISAs were interpolated from this standard
curve and used for comparisons.
2.9. Western blotting
For western blots, alanine-scanning mutant recombinant protein
samples, hT40 recombinant protein samples and all brain lysate sam-
ples were prepared in Laemmli buffer (ﬁnal 1× composition: 20 mM
Tris, pH 6.8, 2% SDS, 6% glycerol, 1% β-mercaptoethanol, 0.002%
Bromophenol Blue). All sampleswere heated at 99 °C for 5min and sep-
arated using Criterion TGX Precast 4–20% gels (BioRad, Hercules, CA,
#567-1094 and #567-1095) in SDS-PAGE. Proteins were then trans-
ferred to BioTrace NT nitrocellulose transfer membrane (Pall Life Sci-
ences, Port Washington, NY, #66593) at 400 mA for 50 min. For the
scanning alaninemutant protein blots, 400 ng of each protein was load-
ed for the TNT1, TNT2, and Tau12blots and 100ngof proteinwas loaded
for the Tau13 blot. Recombinant samples, containing a C-terminal 6×
histidine tag, for each of the tau isoforms (hT40, hT39, hT34, hT37,
hT24, and hT23) were diluted to 0.5 μM in TBS and loaded at 20 μl for
the isoform blots. The rodent brain lysate tau blots were loaded with
80 μg of total protein for the TNT1 blot and 20 μg of total protein for
the TNT2, Tau12, and Tau13 blots. 187 ng of the puriﬁed recombinant
tau protein monomer and aggregate samples were loaded per lane.
The human frontal cortex lysates from controls (n = 3) and AD (n =
3) were loaded at 60 μg/lane of total protein for the TNT1 and TNT2
blots and 20 μg/lane for the Tau12 and Tau13 blots. After a blocking
step of 1 h with 2% milk/TBS, the membranes were probed overnight
at 4 °C with primary antibodies. All antibody stocks were 1 mg/ml and
diluted in 2% milk/TBS. The scanning alanine mutant blots and tau iso-
form blots were probed with TNT1 (1:100,000), TNT2 (1:10,000),
Tau12 (1:500,000), or Tau13 (1:1,000,000) then reprobed with R1
(1:20,000) to normalize the N-terminal antibody signal for the scanning
alaninemutant quantitation. The rodent brain lysateswere probedwith
TNT1 (1:100,000), TNT2 (1:25,000), Tau12 (1:500,000), or Tau13(1:500,000) as well as for GAPDH (1:2000, Cell Signaling D16H11 XP
Rb, Danvers, MA) to serve as a loading control. The Tau12 and Tau13
blots were reprobed with R1 (1:100,000) to conﬁrm the presence of
tau. The puriﬁed recombinant tau monomer and aggregate blots were
probed with TNT1 (1:200,000), TNT2 (1:25,000), Tau12 (1:500,000),
or Tau13 (1:500,000) and R1 (1:10,000) also was used on all blots.
The human frontal cortex lysate blots were incubated with TNT1
(1:100,000), TNT2 (1:10,000), Tau12 (1:500,000), or Tau13
(1:500,000) and also probed for GAPDH (1:2000, Cell Signaling
D16H11 XP Rb,) as the loading control to normalize N-terminal tau sig-
nals. Blotswere rinsedwith 0.1% Tween20/TBS and then incubatedwith
appropriate secondary antibodies diluted 1:20,000 in milk/TBS (IRDye
680RD goat anti-mouse IgG (H + L), #926-68070; and IRDye 800CW
goat anti-rabbit IgG (H + L), #926-32211; both from Li-Cor Bisciences,
Lincoln, NE). Blots were imaged using a Li-Cor Odyssey infrared imaging
system in the 700 and 800 nm channels at 42 μm resolution. Signal in-
tensity of bands was quantiﬁed using Li-Cor ImageStudioLite 5.2 Soft-
ware. The scanning alanine mutant blot signals were normalized to
R1. Three replicates of recombinant monomer and aggregated hT40
were quantiﬁed and normalized to R1 signal. The signals from the
human frontal cortex control and AD samples were quantiﬁed and nor-
malized to GAPDH signals.
2.10. Human tissue immunohistochemistry (IHC)
Hippocampal sections from control (Braak I–II, n = 3), mild AD
(Braak III–IV, n = 3), and severe AD (Braak V–VI, n = 3) cases from
the Brain Bank of the Cognitive Neurology andAlzheimer's Disease Cen-
ter at Northwestern University (see Supplemental Table 1 for details on
human subjects) were used to evaluate the pattern of IHC staining with
TNT1, TNT2, Tau12, Tau13, and PHF1 using established methods
(Kanaan et al., 2012, 2011). Wash steps were performed 6× for
10min in 0.1% Triton-X/TBS between all steps in the procedure. The tis-
suewaswashed and then incubated in 3% hydrogen peroxide to quench
endogenous peroxidase activity for 1 h at RT. The tissue was then
blocked in blocking buffer (10% goat serum/2% BSA/0.4% Triton-X in
TBS) followed by incubation in the primary antibody (diluted in 2%
goat serum/0.1% Triton-X/TBS) overnight at 4 °C. The following dilu-
tions from 1 mg/ml stocks were used: TNT1 1:350,000, TNT2
1:200,000, Tau12 1:450,000, Tau13 1:450,000, PHF1 1:20,000. Initial
titering experiments ensured that all antibodies were used at optimal
dilutions. The following day, the tissue was incubated with a biotinylat-
ed goat anti-mouse IgG (H + L) secondary antibody (Vector Laborato-
ries, BA-9200) diluted 1:500 in 2% goat serum/0.1% Triton-X/TBS for
2 h at RT. Then the tissue was incubated in ABC solution (1 drop of solu-
tions A and B/10 ml, Vector Laboratories, PK-6100) for 1 h at RT follow-
ed by development in 0.05% 3,3′-diaminobenzidine (DAB), 0.003%
hydrogen peroxide, 0.1% Triton-X/TBS for 8 min. After development,
the tissue was mounted and coverslipped with Cytoseal 60 mounting
media (Thermo Fisher Scientiﬁc, #8310-16). Tissue sections from each
case were processed simultaneously for each antibody staining to re-
duce variability between staining runs. Omission of primary antibody
was run to ensure that the speciﬁcity of the IHC signalwasdue to tau an-
tibody reactivity, and as expected, no signalwas observedwith antibody
omission (data not shown) as noted previously (Kanaan et al., 2015).
2.11. Human tissue IHC quantitation
Tissue sections were imaged at 20× magniﬁcation. A reticle
(750 × 750 μm)was used to analyze regions in the CA1/CA2 pyramidal
neuron layer of each case (total area= 2.8–4.5mm2). Neurons inside of
the region were counted and sorted into groups based on established
criteria of theprogressive patterns of taudeposition/aggregation in neu-
rons during pathology evolution (Bancher et al., 1989, 1991; Braak et al.,
1994). Here we used the terminology of Braak and colleagues (Braak et
al., 1994). Examples of each group are found in Fig. 5 and Supplemental
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tau pathology, often extending far into the processes, were classiﬁed
as group 1 cells. Group 2 neurons displayed a combination of granular
cytoplasmic pathology and compact inclusions that were rod-like and
globular in morphology, along with reduced reactivity in processes.
Group 3 neurons were the compact, classic ﬂame-shaped NFTs in the
somatodendritic compartment and the cells no longer had reactivity
in the distal end of the processes. Neurons beyond this phenotype
(e.g. group 4 or ghost tangles, the extracellular remains of neurons
that once contained NFTs and that no longer have nuclei) were not
readily apparent, which was conﬁrmed with the immunoﬂuores-
cence studies described below. The total cell density was used as
the main comparison across disease stages, and to further deter-
mine the relative amount of the different phenotypes (i.e., group
1–3 cells) identiﬁed by each antibody, the counts for each pheno-
type were converted to percent of the total cells labeled for each in-
dividual case and the mean values were compared across disease
stages.2.12. Human tissue immunoﬂuorescence (IF)
Human hippocampal sections (all of the same cases as in IHC) were
co-stained using combinations ofmarkers to conﬁrmwhether TNT anti-
bodies colocalize with early and late tau pathology. The ﬁrst series of
sections were triple stained with TNT1, TNT2 or PHF1, ThR, and DAPI.
ThR (Sigma–Aldrich, S570435) is a marker for β-pleated sheet protein
structure associated with mature tau ﬁbrils (Mena et al., 1995), and
stored at−20 °C as a 1% stock solution (diluted in dH2O). DAPI, a nucle-
armarker (Kapuscinski, 1995), was stored as a stock solution of 5mg/ml
in DMSO and frozen at−20 °C. The tissue was washed between steps
and blocked as above. Primary antibodies were diluted in 2% goat
serum/0.1% Triton-X/TBS from 1 mg/ml stocks: TNT1 1:15,000, TNT2
1:15,000, or PHF1 1:3000. Initial titering experiments ensured all anti-
bodies were used at optimal dilutions. Then the tissue was incubated
in secondary antibody (AlexaFluor goat anti-mouse IgG (H + L) 488;
1:500; Invitrogen, Carlsbad, CA, #A-11001) for 2 h at room temperature.
The ﬁrstwash after secondary contained DAPI at a ﬁnal concentration of
0.5 ng/μl. After the remaining washes, the tissue was rinsed in deion-
ized water for 2 × 3 min then incubated in 0.004% ThR/dH20 for
20 min before 2 × 3 min washes in water. After mounting, autoﬂuo-
rescence was blocked by equilibrating in 70% ethanol for 2 min, incu-
bating in 2% sudan black B, 70% ethanol for 4min, brieﬂy rinsed 3× in
70% ethanol, and washed in water 2 × 3 min. The slides were
coverslipped with Vectashield aqueous mounting media (Vector
laboratories, H-1000).
A second series of sections was quadruple labeled for TNT1 or TNT2,
Alz50, ThR, and DAPI using the same protocol as above with the follow-
ing primary antibody dilutions from1mg/ml stocks: TNT1 1:10,000 and
TNT2 1:10,000. The Alz50 antibody, which identiﬁes a discontinuous
epitope related to an altered conformation that occurs early during
pathological accumulation of tau (Carmel et al., 1996; Hyman et al.,
1988; Jicha et al., 1997), was diluted 1:1000 from a 5.7 mg/ml stock.
AlexaFluor goat anti-mouse IgM 647 (1:500; Invitrogen, #A-21238)
was included with an AlexaFluor goat anti-mouse IgG1 488 (1:500;
Invitrogen, #A-21121).
All IF-stained tissue was imaged using a Nikon A1+ scanning confo-
cal microscope system equipped with 405, 488, 541, and 640 laser lines
and 425–475 nm (DAPI), 500–500 nm (AlexFluor 488), 570–620 nm
(ThR), 663–738 (Alz50) emission ﬁlter sets. Z-stacks were acquired at
0.5 μm step sizes and images for ﬁgures were generated by using the
maximum intensity projections. Control sections were performed by
omitting a single component (TNT1 antibody, TNT2 antibody, ThR, or
Alz50 antibody), and as expected, each signalwas speciﬁc for the appro-
priate marker (data not shown) as previously observed (Kanaan et al.,
2015).3. Statistical analysis
All curve ﬁtting and statistical analyses were performed using
GraphPad Prism 6 software. The recombinant hT40 western blot data
were compared using a paired t-test (with pairsmade from the same re-
actionmix as described above). The tau concentration values calculated
from the human frontal cortex lysate ELISAs (described above) were
compared using an unpaired t-test. The human frontal cortex lysate
western blot quantitative values were compared using an unpaired t-
test. The total cell density data and percentage of cell phenotype data
were analyzed for correlations with advancing Braak stage using the
Spearman rank correlation test. All tests were two-tailed with signiﬁ-
cance set at p b 0.05.
4. Results
4.1. Antibody epitopes map to similar but distinct areas
We used a series of alanine mutant hT40 proteins (between amino
acids 2–24) to further reﬁne the epitopes of each antibody (Fig. 1A) be-
yond the previously reported epitopes (all within the ﬁrst 24 amino
acids of tau). Mutation of amino acids 7–12 eliminated TNT1 and
TNT2 reactivity, but in general, TNT2 appeared less effective in western
blots than TNT1, as indicated by the lower R1 normalized signal values
(Fig. 1A–C). It is noteworthy that deletion of amino acids 2–18 did not
prohibit R1 binding conﬁrming that this polyclonal contains epitopes
outside of the extreme amino terminus (Berry et al., 2004) and suggests
N-terminal antibody labeling will not block R1 binding (Fig. 1A). The
epitope map for both Tau12 and Tau13 displayed quite different pat-
terns of reactivity compared to TNT1 and TNT2 (Fig. 1F). Both antibodies
appeared to identify a discontinuous epitope because reactivity was
substantially reduced or eliminated in the X8-9A, X13-17A, and X18-
21Amutation proteins (Fig. 1D, E). Notably, none of the alaninemodiﬁ-
cations completely eliminated Tau13 reactivity but the antibody did not
react with the Δ2–18 tau protein (deletion of amino acids 2–18) sug-
gesting some reliance on the presence of these amino acids even though
the alanine mutations alone were insufﬁcient to completely disrupt
binding. Each antibody's binding afﬁnitywas identiﬁedusing an indirect
ELISAwith full-length tau protein (Fig. 1G). All of themonoclonal N-ter-
minal antibodies tested here are very high-afﬁnity reagents. TNT1
reached half of the binding saturation at 4.86 ng/ml (32.4 pM) and
TNT2 at 9.21 ng/ml (61.4 pM). Tau13 demonstrated the strongest afﬁn-
ity for tau, reaching half of its binding saturation at 2.51 ng/ml
(16.73 pM) while Tau12 bound half of its maximum at 3.27 ng/ml
(21.8 pM). All N-terminal antibodies were speciﬁc to tau (i.e., no reac-
tivity with tau knockout lysates) and both TNT antibodies labeled
human and rodent tau, while Tau12 and Tau13 were human speciﬁc
(Supp. Fig 1).
4.2. TNT1 and TNT2 preferentially bind aggregated tau and binding is con-
formation dependent
Next, wemeasured the abilities of each antibody to detect patholog-
ical aggregated forms of tau in a non-denaturing sandwich ELISA. Vary-
ing concentrations of monomeric and aggregated full-length
recombinant tau protein were incubated with each of the antibodies.
The TNT1 and TNT2 antibodies did not capture detectable levels of mo-
nomeric tau (TNT1 and TNT2: EC50= undetermined) except at 200 nM
(9.3 ng/μl or 467 ng/well), the highest concentration tested (Fig. 2A and
B). In contrast, robust reactivity was seen with aggregated tau at much
lower concentrations (TNT1: EC50= 6.0 nM; TNT2: EC50= 2.6 nM), in-
dicating a clear difference in reactivity between the two states of the tau
proteins. Tau12 reacted well with monomeric tau (EC50 = 6.9 nM) and
aggregated tau (EC50= 2.5 nM), but the preference for aggregated over
monomeric tau was less robust compared to the TNT antibodies (Fig.
2C). Tau13 demonstrated very similar afﬁnities for tau monomers
Fig. 1. Antibodies recognize similar but distinct epitopes with high afﬁnity (A–E) The epitopes were mapped using scanning alaninemutant tau proteins in western blots. (A) TNT1 reactivity
was eliminated upon mutating amino acids 7–12. Similarly, TNT2 reactivity was disrupted with mutation of amino acids 7–12, and TNT2 displayed less reactivity in general compared to
the other antibodies in western blotting. The Tau12 epitope (previously mapped to 2–23 (Horowitz et al., 2004)) was discontinuous asmutating amino acids 8–9 and 13–21 had a strong
impact on reactivity. Tau13 is a very high-afﬁnity antibody (previously mapped to 9–18 (Garcia-Sierra et al., 2003)), and similar to Tau12, reactivity for Tau13 was affected by mutating
amino acids 8–9, and 13–21. Notably, none of the alanine mutant constructs completely eliminated reactivity, but deletion of amino acids 2–18 completely eliminated reactivity as before
(Garcia-Sierra et al., 2003). The R1 tau antibody, a rabbit polyclonal total tau antibody with epitopes throughout the protein (i.e., unaffected by mutant protein changes), was used to
identify total levels of all protein constructs. (B–E) Signal intensity was quantiﬁed for (B) TNT1, (C) TNT2, (D) Tau12, and (E) Tau13 and normalized to R1 signal to conﬁrm
elimination/reduction in reactivity with each recombinant tau protein. (F) A schematic representing the speciﬁc epitopes for each antibody (TNT1 and TNT2: 7–12; Tau12 and Tau13:
8–9, 13–21) and showing sequence alignments between the ﬁrst 24 amino acids of human tau. (G) N-terminal antibody-binding afﬁnities for full-length recombinant tau in indirect
ELISAs. The antibodies (ranging from 48.8 pg/ml to 100 ng/ml) were incubated with recombinant tau (100 ng/well) bound to a titer ELISA plate. The data were ﬁt to a sigmoidal dose–
response curve and EC50 values were determined (vertical lines), indicating the antibody concentration at which half of the maximum signal is obtained. TNT1 (black circles) EC50 =
4.86 ng/ml, TNT2 (blue squares) EC50 = 9.21 ng/ml, Tau12 (red diamonds) EC50 = 3.27 ng/ml, Tau13 (green triangles) EC50 = 2.51 ng/ml.
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mation-dependent nature of reactivity with these N-terminal antibod-
ies was conﬁrmed by denaturing the same tau samples used in the
ELISAs with SDS, a reducing agent, and heat exposure before immuno-
blotting. All of the antibodies bound equally well to monomer and ag-
gregated tau samples in a denatured state (Fig. 2E–F).
4.3. TNT1 and TNT2 display conformation-dependent recognition of patho-
logical tau from Alzheimer's disease brain lysates
Soluble and sarkosyl-insoluble tau fractions from the frontal cortex
of age-matched controls and Alzheimer's disease cases were used in
TNT1, TNT2, Tau12, Tau13, and PHF1 non-denaturing sandwich ELISAs
to determine the antibodies' abilities to identify aggregated and soluble
pathological forms of tau from the human brain. In the soluble tau frac-
tion, the TNT1 and TNT2 antibodies detected signiﬁcantly more soluble
tau in the Alzheimer's disease brain lysates compared to the control
samples (Fig. 3A). In contrast, Tau12 and Tau13 reacted equally as
well to tau in the control and Alzheimer's disease samples. PHF1was in-
cluded for its ability to speciﬁcally identify pathological forms of tau
and, like TNT1 and TNT2, its signal was signiﬁcantly greater in samples
from Alzheimer's disease cases when compared to age-matched con-
trols. Next, the sarkosyl-insoluble fractions were assayed in thesandwich ELISAs with each antibody. All of the tested antibodies detect-
ed signiﬁcantly more insoluble tau from the Alzheimer's disease cases
when compared to control cases (Fig. 3B). Finally, the conformation de-
pendence of reactivity for TNT1, TNT2, Tau12, and Tau13was conﬁrmed
using denaturing western blots of the soluble tau samples from three of
the same control and Alzheimer's disease cases. All of the antibodies
displayed similar recognition of tau from the control and Alzheimer's
disease brain lysates in denaturing conditions (Fig. 3C–D). The signal in-
tensities were normalized to GAPDH signals to account for any differ-
ences in sample loading. This is in direct contrast to the non-
denaturing ELISAs where TNT1 and TNT2 had dramatically stronger re-
activity to tau in Alzheimer's disease lysates compared to control lysates
(Fig. 3A–B). The pan-tau antibody, R1,wasused to conﬁrm similar levels
of tau thatwere present in control andAlzheimer's disease samples. The
normalized intensities associated with Tau12 and Tau13 were much
higher than those of TNT1 and TNT2 even though less total lysate was
loaded indicating better performance in denaturing western blots. The
relatively weak labeling by TNT1 and TNT2 in human sample western
blotting may appear to suggest they do not recognize all tau isoforms.
We used western blotting to probe recombinant tau isoform proteins
(hT40, hT39, hT34, hT37, hT24, and hT23) with TNT1, TNT2, Tau12.
and Tau13 to address this concern. Each of these N-terminal antibodies
labeled all six human isoforms (Supp. Fig. 2).
Fig. 2. TNT1 and TNT2 binding is selective for aggregated tau and is conformation dependent
(A–D). The binding afﬁnity of (A) TNT1, (B) TNT2, (C) Tau12, and (D) Tau13 for
monomeric and aggregated recombinant tau samples (ranging from 12.2 pM to
200 nM) were measured using sandwich ELISAs (n = 3; mean ± SEM). (A) TNT1
showed reactivity with aggregated tau (black circles) starting at 3.125 nM (EC50 =
6.0 nM) but did not detect monomeric tau (red squares) until it reached 200 nM
(EC50 = undetermined). (B) Similarly, TNT2 robustly reacted with aggregated tau
starting at 0.781 nM (TNT2: EC50 = 2.6 nM) but did not detect monomeric tau until it
reached 200 nM (EC50 = undetermined). (C) Tau12 displayed a slight preference for
aggregated tau (EC50 = 6.9 nM) over monomeric tau (EC50 = 2.5 nM). (D) Tau13
recognized monomeric (EC50 = 1.9 nM) and aggregated (EC50 = 1.1 nM) tau similarly
at all concentrations. (E) The same monomer and aggregated tau samples were
denatured and run on SDS-PAGE/western blots to determine whether the aggregated
tau-selective reactivity was conformation-dependent. Representative blots with TNT1,
TNT2, Tau12, and Tau13 demonstrating equal reactivity to the denatured monomeric
and aggregated samples (top). Equivalent amounts of tau were conﬁrmed with R1, a
pan-tau antibody (bottom). (F) The signal intensities associated with each antibody's
reactivity to monomeric (red squares) and aggregated (black circles) tau samples were
quantiﬁed and normalized to the R1 values. This quantitation showed equal reactivity in
western blots with TNT1: p = 0.593, t(2) = 0.630; TNT2: p = 0.550, t(2) = 0.713;
Tau12: p= 0.368, t(2) = 1.153; Tau13: p= 0.742, t(2) = 0.378 (compared with paired
t-tests).
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of Alzheimer's disease
Next, we aimed to establish the pattern of tau pathology labeled by
each N-terminal antibody and PHF1 in human hippocampal brain slices
from Braak stages I–II, II–IV, and V–VI cases. TNT1, TNT2, Tau12, Tau13,
and PHF1 labeled the typical forms of Alzheimer's disease tau pathology,
including NFTs, neuropil threads, and neuritic plaques (Fig. 4A–O). As
expected, the total number of cells containing TNT1, TNT2, Tau12,
Tau13, and PHF1 showed strong positive correlations with advancing
Braak stage (Fig. 4P, see ﬁgure legend for statistics). One distinct differ-
ence between the TNT antibodies and Tau12 or Tau13 was the extent of
parenchymal tau labeled. TNT1 (Fig. 4A, F, K) and TNT2 (Fig. 4B, G, L)
label little to no parenchymal tau, while both Tau12 (Fig. 4C, H, M)
and Tau13 (Fig. 4D, I, N) robustly label parenchymal tau, which is pre-
sumably non-pathological or normal tau within the tissue. Similar to
the TNT antibodies, PHF1 did not readily label parenchymal tau (Fig.
4E, J, O).
We quantiﬁed neurons of speciﬁc tau pathology phenotypes based
on established criteria describing neurons as group 1 (early pre-tangles,
Fig. 5A), group 2 (intermediate tangles, Fig. 5B) ,and group 3 (classic
mature tangles, Fig. 5C) (Braak et al., 1994). Additional representative
high-magniﬁcation images of neurons from groups 1–3 (taken from a
Braak stage III–IV case) are displayed in Supplemental Fig. 3. The data
are presented as a percentage of the total cells to compare changes in
the proportion of each phenotype across the Braak stages (Fig. 5D–H).
The percentage of TNT1-, TNT2-, Tau12-, Tau13-, and PHF1-positive
group 1 neurons showed strong, signiﬁcant negative correlations with
Braak stages, while group 3 cells showed a strong, signiﬁcant positive
correlation with increasing Braak stage (Table 1). None of the group 2
cells were signiﬁcantly correlated with Braak stage, except PHF1
group 2 neurons, which showed a strong, signiﬁcant negative correla-
tion (Table 1).
The majority of TNT1-positive cells were group 1 (59%) and 2 (41%)
cells compared to group 3 (0.5%) cells in Braak stage I–II cases (Fig. 5D).
In Braak III–IV cases, TNT1 labeled similar but decreasing proportions of
each phenotype (group 1: 42%, group 2: 33%, group 3: 25%), while the
majority were group 3 cells (55%) when compared to group 1 (21%)
and 2 (24%) cells in Braak V–VI cases. Similarly, TNT2 primarily labeled
group 1 (57%) and group 2 (29%) cells compared to group 3 (15%) cells
in Braak I–II cases, while similar amounts of each phenotype were la-
beled (group 1: 42%, group 2: 27%, group 3: 31%) in Braak III–IV cases
(Fig. 5E). In Braak V–VI cases, the majority were group 3 cells (group
1: 32%, group 2: 29%, group 3: 39%). Tau12 labeled more group 1 cells
(58%) compared to group 2 (33%) and group 3 cells (10%) in Braak I–II
cases (Fig. 5F). The antibody labeledmore group 3 cells (51%) compared
to groups 1 (21%) and 2 (28%) cells in Braak III–IV and more group 3
cells (52%) compared to group 1 (19%) and 2 (30%) cells in Braak V–VI
cases as well. Tau13 labeled more group 1 cells (72%) compared to
group 2 (28%) and 3 cells (0.6%) in Braak I–II cases (Fig. 5G). Similar pro-
portions of each phenotype (group 1: 29%, group 2: 40%, group 3: 31%)
were identiﬁed with Tau13 in Braak III–IV cases, while in Braak V–VI
cases, more group 3 cells (55%) were labeled when compared to
group 1 (15%) and 2 (30%) cells. PHF1 stained similar amounts of all
three cell phenotypes in Braak I–II (group 1: 28%, group 2: 45%, group
3: 26%) and mostly group 3 cells (48%) in Braak stages III–IV cases
(group1: 22%, group 2: 31%, Fig. 5H). Therewas a robust shift in thepro-
portion of PHF1-labeled group 3 cells (89%) when compared to group 1
(2%) and 2 (9%) cells in Braak stage V–VI cases.
4.5. PAD is exposed in early tau pathology but not late-stage tangles
We performed a series of immunoﬂuorescence co-labeling experi-
ments with TNT1 or TNT2 and ThR, and qualitative evaluations of sec-
tions (using the same cases as in IHC) were performed to identify the
different cell phenotypes and to conﬁrm whether TNT1 and TNT2
Fig. 3. TNT1 and TNT2 recognize pathological but not normal tau dependent upon conformation. TNT1 and TNT2 display conformation-dependent recognition of PAD-exposed tau in
Alzheimer's disease, which is not present in non-demented controls. (A) Soluble protein fractions from human frontal cortex lysates of control and AD brains were used in sandwich
ELISAs using TNT1, TNT2, Tau12, Tau13, or PHF1 as the capture antibody. TNT1, TNT2, and PHF1 all detected signiﬁcantly more tau in AD lysates (black squares) than in control lysates
(red circles) (n= 6; mean ± SEM; ⁎p b 0.05, unpaired t-test, TNT1: t(10) = 4.843, p= 0.0007; TNT2: t(10) = 7.303; p b 0.0001; Tau12: t(10) = 1.228; p= 0.2475; Tau13: t(10) =
0.9758; p = 0.3522; PHF1: (t(10) = 2.504; p = 0.0312)). (B) Sandwich ELISAs were also carried out with sarkosyl-insoluble protein fractions from human frontal cortex lysates of
control and AD brains. Signiﬁcantly more tau was detected in the sarkosyl-insoluble protein fractions from AD lysates than the control lysates with all antibodies (n = 5 for control
and n= 6 AD; mean ± SEM; ⁎p b 0.05, unpaired t-test, TNT1: (t(9) = 2.923; p= 0.0169), TNT2: (t(9) = 4.301; p= 0.002), Tau12: (t(9) = 3.228; p= 0.0103), Tau13: (t(9) = 2.398;
p= 0.04) and PHF1: (t(9) = 2.264;p= 0.0499)). (C) The soluble fractions for control and AD brains were run under denaturing conditions in western blots. Samples were loaded at
60 μg total protein/lane for TNT1 and TNT2 and 20 μg total protein/lane for Tau12 and Tau13. GAPDH was used as a loading control to conﬁrm equal loading and R1, a pan-tau
antibody, was used to determine the total amounts of tau in the samples. Notably, TNT1 and TNT2 did not work as well as Tau12 or Tau13 in western blot assays. (D) Tau signal
intensities from the control and AD western blots were quantiﬁed and normalized to the GAPDH signal. All antibodies detected similar levels of tau in the control samples (red circles)
compared to the AD samples (black squares) under denaturing conditions (mean ± SEM, p N 0.05 for all comparisons in unpaired t-tests, TNT1: t(4) = 0.234, p = 0.827; TNT2:
t(4) = 0.029, p = 0.978; Tau12: t(4) = 0.451, p = 0.675; Tau13: t(4) = 2.699, p = 0.055). Detection with the pan-tau R1 antibody conﬁrmed that similar amounts of tau were
present in the control and AD samples (mean ± SEM, p N 0.05 for all comparisons in unpaired t-tests, t(4) = 0.881, p = 0.428 (TNT1 blot); t(4) = 0.984, p = 0.381 (TNT2 blot);
t(4) = 1.198, p= 0.297 (Tau12 blot); t(4) = 1.727, p= 0.159 (Tau13 blot)).
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images are displayed in Figs. 6 and 7). TNT1 and TNT2 both labeled
early tau pathology in all disease stages, but the TNT1 and TNT2 reactiv-
ity was lost in several late-stage NFTs, many of which lacked nuclei sug-
gesting they were ghost tangles (Figs. 6 and 7). In the Braak I–II cases,
TNT1 and TNT2 presented a diffuse, granular staining pattern that is
characteristic of group 1 neurons (Figs. 6A and 7A). These inclusions
were ThR negative, indicating a lack of mature ﬁbrillary tau aggregates
containing β-sheet structures. Neurons presenting the granular taustaining pattern were still present in Braak III–IV cases but more com-
pact pathology also appeared (Figs. 6B and 7B) that was positive for
ThR (i.e., group 2 and 3 cells). In Braak V–VI cases, a third distinct pop-
ulation of cells appeared thatwere ThRpositive but negative for TNT1or
TNT2 (likely late group 3 cells or ghost tangles; Figs. 6C and 7C).We also
performed IF staining in hippocampal sections with PHF1 and ThR
(Supp. Fig. 4). Like the TNT antibodies, the PHF1 phosphoepitope was
present in early pre-tangle group 1 cells that were ThR negative in all
Braak stages and also present in ThR-positive group 2 and 3 cells in
Fig. 4. N-terminal antibodies label early tau pathology in the hippocampus and the extent of pathology increases with advancing Braak stage. (A) TNT1, (B) TNT2, (C) Tau12, (D) Tau13, and (E)
PHF1 labeled diffuse, granular pre-tangle neurons in hippocampal neurons of Braak stage I–II cases. Therewas a notable difference in the extent of parenchymal tau labeled by each of the
antibodies. TNT1, TNT2, and PHF1 produced little to no parenchymal tau signal. In contrast, both Tau12 and Tau13 robustly labeled parenchymal tau (i.e., non-pathological tau). (F–J) In
Braak stage III–IV cases, (F) TNT1, (G) TNT2, (H) Tau12, (I) Tau13, and (J) PHF1 detected increased pathology and more compact tau inclusions characteristic of group 2 and 3 neurons.
Tau12 (H) and Tau13 (I) continued to strongly label parenchymal tau, and neuritic threads were not as evident. (K\\O) The extent of (K) TNT1-, (L) TNT2-, (M) Tau12-, and (N) Tau13-
positive pathology continued to increase and early pre-tangle neurons were still present in late-stage cases. (M) Tau12 and (N) Tau13 labeled early tau pathology and parenchymal
tau but at lower levels than in the earlier cases. (O) PHF1 displayed intense reactivity to the tau pathology with the vast majority representing classic NFTs, as well as robust thread
labeling. Examples of neurons with diffuse, granular pre-tangle pathology (i.e., group 1) are identiﬁed with closed arrows, intermediate neurons containing a combination of granular
and compact inclusions (i.e., group 2) are identiﬁed with closed arrowheads, and classic, compact neuroﬁbrillary tangles (i.e., group 3) are identiﬁed with open arrows. Scale bar
represents 100 μm. (P) The cell density of all neurons labeled with each N-terminal antibody (TNT1, red circles; TNT2, blue squares; Tau12, green triangles; Tau13, orange triangles;
PHF1, black diamonds) showed a strong, signiﬁcant positive correlation with increasing Braak stage (TNT1: r= 0.791, p= 0.021; TNT2: r = 0.738, p= 0.037; Tau12: r= 0.738, p=
0.037; Tau13: r= 0.738, p= 0.037; PHF1: r= 0.791, p= 0.021).
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PHF1 negative were infrequent and several apparent ghost tangles
remained PHF1-reactive (Supp. Fig. 4I–L).
Next, we performed multi-label IF with TNT1 or TNT2, ThR, DAPI,
and the Alz50 antibody, an established tau conformation-speciﬁc anti-
body that appears in early pre-tangle neurons, to further conﬁrm that
TNT1 and TNT2 labeled early tau pathology (Carmel et al., 1996;
Hyman et al., 1988; Jicha et al., 1997). Both TNT1 and TNT2 showed ex-
tensive colocalization with Alz50 in all stages of the disease (Supp. Figs.
5 and 6). As above, there were three distinct populations of cells found
through the Braak stages: TNT1+/TNT2+, Alz50+ and ThR− (group 1
cells), TNT1+/TNT2+, Alz50+, and ThR+ (group 2 and 3 cells), or
TNT1−/TNT2−, Alz50−, and ThR+ (late group 3 or ghost tangles).
5. Discussion
Tau dysfunction is likely a key mediator of neurodegeneration in
Alzheimer's disease and other tauopathies; however, the mechanisms
of tau toxicity are not entirely clear. Historically, the amino terminus
of tau has largely been ignored, withmost of the focus placed on themi-
crotubule-binding domains due to their involvement in microtubule
binding and β-sheet formation in tau aggregates. Previous workestablished that the N-terminus is important for other biological func-
tions of tau and tau's role in disease pathogenesis (Brandt et al., 1995;
Horowitz et al., 2006). More recently, our group established that the
ﬁrst 18 amino acids of tau comprise a biologically active motif, called
the phosphatase-activating domain or PAD, and exposure of this motif
is both necessary and sufﬁcient to disrupt anterograde fast axonal trans-
port in squid axoplasm (Kanaan et al., 2011). PAD exposure initiated a
PP1-GSK3β signaling cascade that resulted in phosphorylation of
kinesin light chain and dissociation of bound cargoes (Kanaan et al.,
2011). These studies highlight important characteristics of the amino
terminus and suggest that this region of the molecule is critical in un-
derstanding tau-mediated toxicity. Thus, we have recently shifted our
focus to the PAD motif and here we utilized several N-terminal tau an-
tibodies to examine details about PAD exposure in the context of
human disease.
5.1. Reﬁning N-terminal tau antibody epitopes and characterizing the novel
TNT2 antibody
Performing a detailed characterization of the epitopes of TNT1,
TNT2, Tau12, and Tau13was theﬁrst step in establishing the differences
between these antibodies and determining their abilities to identify
Fig. 5. Percentages of the different phenotypes of tau pathology depositionwithN-terminal tau antibodies in humanhippocampal tissue across Braak stages. (A–C) Representative examples of (A)
a group 1 neuron, (B) two group 2 neurons, and (C) a group 3 neuron. These cellular phenotypes are established previously (Braak et al., 1994). Group 1 cells are characterized by diffuse
granular cytoplasmic staining (arrows), group 2 cells contain diffuse granular staining (arrows) and some discrete regions ofmore compact inclusions (arrowheads), and group 3 neurons
no longer contain diffuse granular staining but contain large compact tangles (arrowhead, i.e., classic NFTs). Scale bars are 25 μm in (A–C). (D–H). The percentage of group 1, 2, and 3 cells
(reported as themeanof thepercents from each casewith error bars representing the SEM),with the total number of cells/mm2 inparentheses (reported as themean of cell densities from
each case), labeled by the (D) TNT1, (E) TNT2, (F) Tau12, (G) Tau13, and (H) PHF1 antibody are compared between the Braak stages. (D) In Braak I–II cases, TNT1 labeledmore group 1 and
2 cells compared to group 3 cells. In Braak III–IV cases, TNT1 labeled similar amounts of each phenotype, while in Braak V–VI cases, more group 3 cells were labeled when compared to
group 1 and 2 cells. (E) TNT2 labeled more group 1 cells compared to group 3 cells, while in Braak III–IV cases, similar amounts of each phenotype were labeled, and in Braak V–VI
cases, the majority were group 3 cells. (F) In Braak I–II cases, Tau12 labeled more group 1 cells compared to group 2 and 3 cells. In both Braak III–IV and V–VI cases, Tau12 labeled
more group 3 cells compared to group 1 and 2 cells. (G) Tau13 labeled more group 1 cells compared to group 2 and 3 cells. Similar proportions of each phenotype were identiﬁed with
Tau13 in Braak III–IV cases, while in Braak V–VI cases more group 3 cells were labeled when compared to group 1 and 2 cells. (H) PHF1 stained similar amounts of all three cell
phenotypes in Braak I–II and more group 3 cells compared to groups 1 and 2 in III–IV cases. A dramatic increase in PHF1 labeled group 3 cells was observed in Braak V–VI cases.
27B. Combs et al. / Neurobiology of Disease 94 (2016) 18–31PAD exposure. A peptide of amino acids 2–18 in tau was used to raise
TNT1 and TNT2, but through the use of a scanning alaninemutation ap-
proach, we reﬁned the epitope of both TNT antibodies to amino acids 7–
12. Mutations at the edges of the TNT1 and TNT2 epitopes partially
disrupted antibody binding, and overall, these antibodieswere not as ef-
fective in denaturing western blots compared to Tau12 and Tau13, fur-
ther supporting that optimal TNT1 and TNT2 reactivity is dependent on
native conformation. Finally, we demonstrated that all of theseN-termi-
nal antibodieswere speciﬁc for tau (no reactivity in tau knockoutmouse
samples) and both TNT antibodies cross-react with mouse and rat tau,
despite two amino acid differences (i.e., E9D and V10T) between
human and rodent tau.Using larger deletion constructs, the Tau12 epitope was previously
mapped to amino acids 2–23 (Horowitz et al., 2004) and the Tau13 epi-
tope to within amino acids 9–18 (Garcia-Sierra et al., 2003; Ghoshal et
al., 2002). The alanine mutation approach showed that Tau12 and
Tau13 have discontinuous epitopes composed of amino acids 8–9 and
13–21, but some differences were noted. For example, changing
amino acids 8 and 9 completely disrupted reactivity of Tau12 but not
Tau13. In fact, the reactivity of the Tau13 antibody was not completely
abolished with any of these discrete modiﬁcations, likely due to the
very high afﬁnity of this antibody (highest of those tested here). Howev-
er, coupling these data with previous deletion construct data
(Garcia-Sierra et al., 2003; Ghoshal et al., 2002), as well as a lack of
Table 1
Correlations between Braak stages and group 1, group 2, or group 3 cell phenotypes la-
beled with TNT1, TNT2, Tau12, Tau13, and PHF1.
Tau antibody Cell phenotype % Labeled cells vs Braak stage (r value)
TNT1 Group 1 −0.843⁎
Group 2 −0.580
Group 3 0.953⁎
TNT2 Group 1 −0.715⁎
Group 2 0.053
Group 3 0.738⁎
Tau12 Group 1 −0.791⁎
Group 2 −0.158
Group 3 0.791⁎
Tau13 Group 1 −0.896⁎
Group 2 0.105
Group 3 0.953⁎
PHF1 Group 1 −0.896⁎
Group 2 −0.843⁎
Group 3 0.843⁎
⁎ p b 0.05 in Spearman rank correlation test.
28 B. Combs et al. / Neurobiology of Disease 94 (2016) 18–31reactivity to theΔ2–18 tau deletion construct shown here, suggests that
the important amino acids in the Tau13 epitope are 8–9 and13–21. Both
Tau12 and Tau13 are sensitive and, as previously reported (Petry et al.,
2014), human-speciﬁc antibodies (i.e., lack reactivity with all rodent
tau), which is consistent with the absence of human amino acids 19–
28 in rodent tau and further supports a distinction between the epitope
of these and the TNT antibodies.Fig. 6.Multi-label ﬂuorescent stain indicates TNT1 detects early tau pathology in disease. Qualitativ
pathology, remained in classic NFTs, butwas absent in later stage NFTs (e.g. ghost tangles). Repr
marker of PAD-exposed tau), ThR (B, F, J; red, β-sheet structure present in classic NFTs), and DA
pre-tangles in Braak I–II that were ThR negative (solid arrow). (E–H) TNT1 identiﬁed neurons
(open arrow) in Braak stages III–IV. Occasional late-stage NFTs (e.g. ghost tangles lacking nu
label ThR-negative structures (solid arrow) in Braak V–VI, as well as more mature ThR-positiv
ThR negative. Many ThR-positive cells were TNT1 negative and did not have nuclei (i.e., ghost5.2. Differential reactivity among N-terminal antibodies and identiﬁcation
of PAD exposure
Previously, we have shown that TNT1 is a marker of PAD exposure
and that this event occurs early in the progression of Alzheimer's dis-
ease. Establishing whether this was true for all N-terminal antibodies
was important for understanding more about PAD exposure in
Alzheimer's disease. We signiﬁcantly extend these ﬁndings with TNT1
and show that TNT2 behaves similarly as a marker of PAD exposure. In
contrast, other N-terminal antibodies, with slightly different epitopes,
do not function as pathological, PAD exposure-speciﬁcmarkers and rec-
ognize all forms of tau similarly. Despite its reputation as an “intrinsical-
ly disordered” protein, tau is known to exist in a global conformation
and contains regions of important secondary structure (Jeganathan et
al., 2006; Mukrasch et al., 2009). PAD exposure is heavily dependent
upon tau conformation (Jeganathan et al., 2008; Kanaan et al., 2011).
In native-state biochemical assays, both TNT1 and TNT2 show remark-
able selectivity and strong reactivity with pathological tau (e.g., aggre-
gated recombinant protein and tau from Alzheimer's disease brains),
but not normal tau (e.g., recombinant monomers or tau from control
brains). Importantly, the R1 antibody used for detection in these assays
is a polyclonal antibodywith epitopes throughout the entire tau protein
(Berry et al., 2004) suggesting that these N-terminal antibodies will not
negatively affect R1 binding. Indeed, deletion of amino acids 2–18 did
not eliminate R1 reactivity in western blots, and pre-labeling tau with
N-terminal antibodies does not appreciably affect R1 binding in indirect
ELISAs (unpublished observation). The dependence of conformatione assessment of TNT1 reactivity conﬁrmed that PAD exposure occurred in early, pre-tangle
esentativemulti-label ﬂuorescent stain imageswere capture to showTNT1 (A, E, I; green, a
PI (C, G, K; blue, nuclei). Merged images are shown in (D, H, L). (A–D) TNT1 labeled diffuse
that are ThR negative (solid arrow) and more compact classic NFTs that are ThR positive
clei) were ThR positive and TNT1 negative (solid arrowhead). (I–L) TNT1 continued to
e NFT inclusions (open arrow). Notably, the vast majority of TNT1-positive threads were
tangles) in the later disease stages (solid arrowhead). Scale bars represent 50 μm.
Fig. 7.Multi-label ﬂuorescent stain indicates TNT2 detects early tau pathology in disease. Qualitative assessment of TNT2 reactivity conﬁrmed that PAD exposure occurred in early, pre-tangle
pathology, remained in classicNFTs butwas absent in later stageNFTs (e.g. ghost tangles). Representativemulti-label ﬂuorescent stain imageswere captured to showTNT2 (A, E, I; green, a
marker of PAD-exposed tau), ThR (B, F, J; red, β-sheet structure present in classic NFTs), and DAPI (C, G, K; blue, nuclei). Merged images are shown in (D, H, L). (A–D) TNT2 labeled diffuse
pre-tangles in Braak I–II that were ThR negative (solid arrow). (E–H) TNT2 identiﬁed neurons that are ThR negative (solid arrow), as well as more compact classic NFTs that are ThR
positive (open arrow) in Braak stages III–IV. Occasional late-stage NFTs (e.g. ghost tangles lacking nuclei) were ThR positive and TNT2 negative (solid arrowhead). (I–L) TNT2
continued to label ThR-negative structures (solid arrow) in Braak V–VI, as well as more mature ThR-positive NFT inclusions (open arrow). Like TNT1, the vast majority of TNT2-
positive threads were ThR-negative and many of ThR-positive cells were TNT2 negative and did not have nuclei (i.e., ghost tangles; solid arrowhead). Scale bars represent 50 μm.
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tau in denaturing SDS-PAGE western blots. Additionally, these antibod-
ies demonstrated very high afﬁnity for monomeric recombinant tau in
indirect ELISAs suggesting the protein undergoes denaturation upon
binding to the polystyrene plate, which has been noted with other pro-
teins (Hollander and Katchalski-Katzir, 1986; Shields et al., 1991). TNT2
appears to be more sensitive to these conformational changes as evi-
denced by its greater reactivity in the non-denaturing assays as well
as its stronger labeling of tau pathology in human tissue.
The uniqueness of the TNT1 and TNT2 reactivity proﬁle is further
highlighted by the lack of such selectivity for pathological tau with
Tau12 and Tau13. These differences in antibody reactivity are directly
related to slight differences in their respective epitopes within the ex-
treme N-terminus of tau. This suggests that reactivity could depend on
a secondary structure within this region that is typically obscured or
not present in monomeric tau but is exposed or stabilized in pathologi-
cal tau. Secondary structure in this region has not been experimentally
demonstrated but an α-helix is predicted to exist from amino acids 7–
12 (Gamblin, 2005). Larger conformational changes could leave this epi-
tope exposed or affect stability of theα-helix, thereby greatly enhancing
antibody reactivity. Interestingly, TNT1 and TNT2, in particular, are less
effective in the denaturing conditions of a western blot, indicating that
some protein structure may enhance reactivity. In contrast, inclusion
of amino acids 13–21 in the epitope of Tau12 and Tau13 appears to
drive the lack of distinction between normal and pathological tau,suggesting that these downstream amino acids are accessible in all
forms of tau.
5.3. Timing of PAD exposure in human disease
The N-terminal antibodies in this study were also used to character-
ize PAD exposure and tau deposition in human post-mortem brain sec-
tions. Reactive neurons were categorized into previously established
phenotypes based on the stage of tau inclusion formation within the
cells (Bancher et al., 1989, 1991; Braak et al., 1994). Previous observa-
tions showing that TNT1 appeared to precede AT8 (Kanaan et al.,
2011), a phosphoepitope that appears early in pathology formation,
suggested that PAD exposure occurred very early in pre-tangle neurons
(Braak et al., 1994; Garcia-Sierra et al., 2000; Kanaan et al., 2012;
Luna-Munoz et al., 2007). Here, we found that TNT1 and TNT2 appear
in Braak I–II stages and do not colocalize with ThR in the diffuse, granu-
lar pre-tangle pathology conclusively demonstrating that PAD exposure
is an early event. As noted previously, ThR ﬂuorescence was largely ab-
sent until the Braak III–IV cases when more compact NFT tau inclusions
form (Mena et al., 1995). Importantly, we show that group 1 and 2 neu-
rons, primarily labeled by TNT1 and TNT2 in the early Braak stages, are
present through the latest Braak stages in roughly the same numbers.
This ﬁnding highlights the asynchronous and continual nature of PAD
exposure and tau inclusion formation during the progression of
Alzheimer's disease. Moreover, our data suggest that early PAD
30 B. Combs et al. / Neurobiology of Disease 94 (2016) 18–31exposure is one of the mechanisms behind soluble and oligomeric tau
toxicity (Kanaan et al., 2011, 2012; Patterson et al., 2011a, 2011b).
The TNT antibodies also label classic NFT-containing group 3 neu-
rons in later Braak stages,which colocalizewith ThR. Apparent ThR-pos-
itive ghost tangles (i.e., without nuclei (Braak et al., 1994)) are no longer
labeled by TNT1 or TNT2, which conﬁrms that PAD exposure is lost in
the latest stages of NFT evolution. The disappearance of TNT labeling is
not unexpected as the loss of the extreme N-terminus in compact
NFTs and ghost tangles were previously reported in several studies
(Bondareff et al., 1994; Dickson et al., 1992; Endoh et al., 1993;
Horowitz et al., 2004). Proteolysis with caspase-6, a known mediator
of tau degradation, particularly at the D13 site, may cause the loss of
TNT antibody reactivity as it does Tau12 reactivity (Guo et al., 2004;
Horowitz et al., 2004). N-terminal cleavage in mature NFTs could have
important implications for tau toxicity in Alzheimer's disease as degra-
dation would include a loss of PAD. This could reduce aberrant PAD-in-
duced PP1-GSK3β signaling and axonal transport defects, potentially
leading to NFTs that are less toxic than oligomers and other pre-tangle
forms of tau pathology. Loss of TNT reactivity also explains the differ-
ences when compared to PHF1, a well-known phosphoepitope in tau
(pS396/pS404) (Greenberg et al., 1992; Otvos et al., 1994), known to
persist in late-stage NFTs (Augustinack et al., 2002). The staining pat-
terns were similar until Braak stages V–VI when PHF1 labeled many
more group 3 and 4 cells (e.g. ghost tangles). These differences support
the notion that modiﬁcations and epitopes are differentially changed
during the evolution of tau pathology.
Tau12 and Tau13 showed similar patterns of reactivity throughout
the different Braak stages, but these antibodies also robustly labeled pa-
renchymal tau. This staining pattern is consistent with labeling normal
endogenous tau proteins (Papasozomenos and Binder, 1987) and is
not surprising considering their inability to differentiate between nor-
mal and misfolded tau in biochemical assays. In contrast, TNT1 and, to
an even greater degree, TNT2 displayed a very strong preference for
pathological tau and little to no parenchymal tau staining. This is one
of the most important distinctions between the TNT antibodies and
the other N-terminal antibodies studied here. Again, this demonstrates
that the PAD exposure phenotype is speciﬁc to pathological forms of tau
and is dependent on effects within the TNT1 and TNT2 epitopes (i.e.
amino acids 7–12) but not the Tau12 and Tau13 epitopes that are just
slightly downstream.
Finally, we performed co-immunoﬂuorescence stains of TNT1 or
TNT2 with Alz50 to determine how these N-terminal antibodies com-
pare to an established marker of early pathological conformational
changes (Carmel et al., 1996; Hyman et al., 1988). Extensive
colocalization existed between the TNT antibodies and Alz50 in all
Braak stages and all cellular phenotypes (i.e., groups 1–3 cells). It is
noteworthy that the epitopes of the TNT and Alz50 antibodies overlap
and that the EC50 value of Alz50 in an indirect ELISA with recombinant
tau (24.50 ng/ml, data not shown) is quite close to that of TNT1 and
TNT2 in molarity (Alz50 has a higher molecular weight as an IgM
while TNT1 and TNT2 are IgG1 antibodies). These data suggest that
there is direct competition for binding sites and this could lead to under-
estimations of each form of tau with these dual label stains. Despite this
limitation, the high level of colocalization suggests the conformations
that give rise to PAD exposure and the discontinuous epitope of Alz50
occur simultaneously in tau pathology. Importantly, the involvement
of additional regions of tau protein for reactivity of Alz50 (Carmel et
al., 1996) andMC1 (Jicha et al., 1997) mitigate their usefulness as direct
markers of PAD exposure.
6. Conclusions
There has long been a link between tau misfolding and tau patholo-
gy. Recent evidence shows that disease-related modiﬁcations of tau
cause abnormal exposure of PAD leading to axonal dysfunction and
highlighting the importance of tau's amino terminus. Here, throughthe use of N-terminal tau antibodies, we examine these changes as tau
progresses from normal to a pathological form. We demonstrate that
TNT1 and TNT2 are strong markers for PAD exposure in pathological
forms of tau while other N-terminal antibodies like Tau12 and Tau13
are unable to differentiate between the two forms. The uniqueness of
the TNT antibodies and their interaction with the pathological changes
associated with these conformational changes are due to their speciﬁc
epitopes (i.e. amino acids 7–12), as it is not replicated with N-terminal
antibodies that bind to locations slightly downstream. Due to the con-
formation-dependent speciﬁcity of TNT1 and TNT2, we provide strong
evidence that PAD exposure occurs early during pathological tau depo-
sition in human brains but the epitope is lost in late neuroﬁbrillary tan-
gles or ghost tangles. Given the previously demonstrated link between
PAD exposure and toxic disruptions in anterograde fast axonal trans-
port, this provides a potential explanation for toxicity associated with
earlier forms of pathological tau but not mature neuroﬁbrillary tangles.
The data support changes in the N-terminus as a key identiﬁer of dys-
functional tau, a ﬁnding that may have important implications for tau
toxicity and the pathogenesis of Alzheimer's disease.
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